Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X. Villanueva C, et al. Among authors: merrouche y. Target Oncol. 2013 Jun;8(2):137-43. doi: 10.1007/s11523-013-0279-4. Epub 2013 Apr 23. Target Oncol. 2013. PMID: 23609057 Clinical Trial.
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Culine S, et al. Among authors: merrouche y. J Clin Oncol. 2003 Sep 15;21(18):3479-82. doi: 10.1200/JCO.2003.12.104. J Clin Oncol. 2003. PMID: 12972523 Clinical Trial.
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K. Massard C, et al. Among authors: merrouche y. Br J Cancer. 2007 Oct 8;97(7):857-61. doi: 10.1038/sj.bjc.6603942. Epub 2007 Sep 18. Br J Cancer. 2007. PMID: 17876336 Free PMC article. Clinical Trial.
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.
Blay JY, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, Saada-Bouzid E, Firmin N, Bertucci F, Marec-Berard P, Ray-Coquard I, Lervat C, Rolland F, Thyss A, Conroy T, Brahmi M, Dufresne A, Merrouche Y, Brunat-Mentigny M, Biron P, Bompas E, Perol D; French Sarcoma Group. Blay JY, et al. Among authors: merrouche y. Eur J Cancer. 2024 Sep;208:114228. doi: 10.1016/j.ejca.2024.114228. Epub 2024 Jul 15. Eur J Cancer. 2024. PMID: 39018632 Free article. Clinical Trial.
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
Négrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel M, et al. Négrier S, et al. Among authors: merrouche y. Br J Cancer. 1992 May;65(5):723-6. doi: 10.1038/bjc.1992.152. Br J Cancer. 1992. PMID: 1586600 Free PMC article. Clinical Trial.
115 results